“As you point out, we don't know how close we came to the 50% magic number. In other words, did the DSMC advise against protocol changes and adding Mortality at Day 42 because they felt confident we'd get a halt at 293? Or did they adopt that approach to ensure we'd succeed at 390?”

Great questions. We as investors and CYDY hope the second interim analysis will result in a halt due to statistically significant efficacy. But as you point out, we don’t know if that’s the exact goal of the 2nd interim analysis or to confirm that the change to 42 days sets the trial on the correct path for full trial analysis. We honestly won’t know until the interim analysis results return with a halt or a decision to continue.